RedHill Biopharma Announces Anticipated Key Milestones For 2015 - Quick Facts

(RTTNews) - RedHill Biopharma Ltd. (RDHL), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, announced selected key milestones and events anticipated in 2015.

The company's upcoming milestones include top-line data expected in the second quarter of 2015 from its first Phase III ERADICATE Hp study with RHB-105 for H. pylori bacterial infection, currently ongoing in the U.S.

In November 2014, the U.S Food and Drug Administration or FDA designated RHB-105 as a Qualified Infectious Disease Product or QIDP under the FDA's Generating Antibiotic Incentives Now Act, intended to encourage new antibiotic drugs for the treatment of serious or life-threatening infections.

RedHill also expects top-line data in the third or fourth quarter of 2015 from its ongoing Phase III study with Bekinda or RHB-102 for acute gastroenteritis and gastritis, known as the GUARD study. Bekinda is used for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting.

As part of its commitment to address unmet medical needs, RedHill said it plans to commence in the coming weeks a first nonclinical research collaboration with a U.S. government agency to test the antiviral activity of a proprietary experimental combination therapy of orally-administered actives for the Ebola virus disease.